Serum immunoglobulin G as a discriminator of infection in follicular lymphoma patients undergoing chemotherapy with bendamustine in combination with rituximab.

MLA

Hirata, Akie, et al. “Serum Immunoglobulin G as a Discriminator of Infection in Follicular Lymphoma Patients Undergoing Chemotherapy with Bendamustine in Combination with Rituximab.” Hematology (Amsterdam, Netherlands), vol. 27, no. 1, Dec. 2022, pp. 384–95. EBSCOhost, https://doi.org/10.1080/16078454.2022.2051863.

APA

Hirata, A., Miyashita, K., Tanaka, T., Hirata, K., Narazaki, T., Utsunomiya, H., Ohno, H., Nakashima, E., Tachikawa, Y., Choi, I., Taguchi, K., & Suehiro, Y. (2022). Serum immunoglobulin G as a discriminator of infection in follicular lymphoma patients undergoing chemotherapy with bendamustine in combination with rituximab. Hematology (Amsterdam, Netherlands), 27(1), 384–395. https://doi.org/10.1080/16078454.2022.2051863

Chicago

Hirata, Akie, Kaname Miyashita, Takafumi Tanaka, Kiyoko Hirata, Taisuke Narazaki, Hayato Utsunomiya, Hirofumi Ohno, et al. 2022. “Serum Immunoglobulin G as a Discriminator of Infection in Follicular Lymphoma Patients Undergoing Chemotherapy with Bendamustine in Combination with Rituximab.” Hematology (Amsterdam, Netherlands) 27 (1): 384–95. doi:10.1080/16078454.2022.2051863.